CITIUS ONCOLOGY, INC.
CTOR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851484
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
19
- +5 vs. Q1 2026
- Total value $9.2M
Superinvestors holding CTOR
0
- None of the superinvestors held CTOR at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by CTOR insiders, newest first.
No open-market purchases or sales by CTOR insiders are on file.
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in CTOR at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 8,705,589 | $5.66M | 0.16% | −483,266−5.3% | Reduced |
| BANK OF AMERICA CORP /DE/ | 3,835,160 | $2.49M | 0.00% | 00.0% | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC | 546,325 | $355.11K | 0.00% | +11,501+2.2% | Added |
| UBS Group AG | 334,619 | $217.5K | 0.00% | +297,779+808.3% | Added |
| GEODE CAPITAL MANAGEMENT, LLC | 245,407 | $159.54K | 0.00% | −19,326−7.3% | Reduced |